NMDA antagonists under investigation for the treatment of major depressive disorder

Bibliography

• Wittchen HU, Jacobi F, Rehm J, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011;21(9):655-79
   PubMed Web of Science ®Google Scholar
• Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003;53(8):649-59
   PubMed Web of Science ®Google Scholar
• Souery D, Papakostas GI, Trivedi MH. Treatment-resistant depression. J Clin Psychiatry 2006;67(Suppl 6):16-22
   PubMed Web of Science ®Google Scholar
• Skolnick P. Antidepressants for the new millennium. Eur J Pharmacol 1999;375(1-3):31-40
   PubMed Web of Science ®Google Scholar
• Szewczyk B, Pałucha-Poniewiera A, Poleszak E, et al. Investigational NMDA receptor modulators for depression. Expert Opin Investig Drugs 2012;21(1):91-102
   PubMed Web of Science ®Google Scholar
• Pilc A, Wieronska JM, Skolnick P. Glutamate-based antidepressants: preclinical psychopharmacology. Biol Psychiatry 2013;73(12):1125-32
   PubMed Web of Science ®Google Scholar
• Nakanishi S. Molecular diversity of glutamate receptors and implications for brain function. Science 1992;258(5082):597-603
   PubMed Web of Science ®Google Scholar
• Niciu MJ, Henter ID, Luckenbaugh DA, et al. Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. Annu Rev Pharmacol Toxicol 2014;54:119-39
   Google Scholar
• Lau CG, Takeuchi K, Rodenas-Ruano A, et al. Regulation of NMDA receptor Ca2+ signalling and synaptic plasticity. Biochem Soc Trans 2009;37(6):1369-74
   PubMedGoogle Scholar
• Cull-Candy S, Brickley S, Farrant M. NMDA receptor subunits: diversity, development and disease. Curr Opin Neurobiol 2001;11(3):327-35
   PubMed Web of Science ®Google Scholar
• Köhr G. NMDA receptor function: subunit composition versus spatial distribution. Cell Tissue Res 2006;326(2):439-46
   PubMed Web of Science ®Google Scholar
• Parsons CG, Quack G, Bresink I, et al. Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 1995;34(10):1239-58
   PubMed Web of Science ®Google Scholar
• Mealing GAR, Lanthorn TH, Murray CL, et al. Differences in degree of trapping of low-affinity uncompetitive N- methyl-D-aspartic acid receptor antagonists with similar kinetics of block. J Pharmacol Exp Ther 1999;288(1):204-10
   PubMed Web of Science ®Google Scholar
• Williams K. Extracellular modulation of NMDA receptors. In: Van Dongen AM, editor. Biology of the NMDA receptor. CRC Press, Boca Raton, FL; 2009. Chatper 11
   Google Scholar
• Skolnick P, Layer RT, Popik P, et al. Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry 1996;29(1):23-6
   PubMed Web of Science ®Google Scholar
• Trullas R, Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 1990;185(1):1-10
   PubMed Web of Science ®Google Scholar
• Skolnick P, Popik P, Trullas R. Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci 2009;30(11):563-9
   PubMed Web of Science ®Google Scholar
• Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000;47(4):351-4
   PubMed Web of Science ®Google Scholar
• Aan Het Rot M, Zarate CA Jr, Charney DS, Mathew SJ. Ketamine for depression: where do we go from here? Biol Psychiatry 2012;72(7):537-47
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006;63(8):856-64
   PubMed Web of Science ®Google Scholar
• Mathews DC, Henter ID, Zarate CA Jr. Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date. Drugs 2012;72(10):1313-33
   PubMed Web of Science ®Google Scholar
• Ibrahim L, Diazgranados N, Luckenbaugh DA, et al. Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression. Prog Neuropsychopharmacol Biol Psychiatry 2011;35(4):1155-9
   PubMed Web of Science ®Google Scholar
• Phelps LE, Brutsche N, Moral JR, et al. Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry 2009;65(2):181-4
   PubMed Web of Science ®Google Scholar
• Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010;67(8):793-802
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Brutsche NE, Ibrahim L, et al. Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 2012;71(11):939-46
   PubMed Web of Science ®Google Scholar
• Price RB, Nock MK, Charney DS, Mathew SJ. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 2009;66(5):522-6
   PubMed Web of Science ®Google Scholar
• DiazGranados N, Ibrahim LA, Brutsche NE, et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry 2010;71(12):1605-11
   PubMed Web of Science ®Google Scholar
• Sanacora G, Smith MA, Pathak S, et al. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol Psychiatry 2013. [ Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Krystal JH, Sanacora G, Duman RS. Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry 2013;73(12):1133-41
   PubMed Web of Science ®Google Scholar
• Blier P, Zigman D, Blier J. On the safety and benefits of repeated intravenous injections of ketamine for depression. Biol Psychiatry 2012;72(4):e11-12
   PubMed Web of Science ®Google Scholar
• Murrough JW, Perez AM, Pillemer S, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 2013;74(4):250-6
   PubMed Web of Science ®Google Scholar
• Shiroma PR, Johns B, Kuskowski M, et al. Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression. J Affect Disord 2014;155(1):123-9
   PubMedGoogle Scholar
• Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997;17(8):2921-7
   PubMed Web of Science ®Google Scholar
• Homayoun H, Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 2007;27(43):11496-500
   PubMed Web of Science ®Google Scholar
• Li N, Lee B, Liu RJ, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010;329(5994):959-64
   PubMed Web of Science ®Google Scholar
• Duman RS, Li N, Liu RJ, et al. Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 2012;62(1):35-41
   PubMed Web of Science ®Google Scholar
• Jernigan CS, Goswami DB, Austin MC, et al. The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2011;35(7):1774-9
   PubMed Web of Science ®Google Scholar
• Chandran A, Iyo AH, Jernigan CS, et al. Reduced phosphorylation of the mTOR signaling pathway components in the amygdala of rats exposed to chronic stress. Prog Neuropsychopharmacol Biol Psychiatry 2013;40(1):240-5
   PubMedGoogle Scholar
• Autry AE, Adachi M, Nosyreva E, et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011;475(7354):91-6
   PubMed Web of Science ®Google Scholar
• Workman ER, Niere F, Raab-Graham KF. mTORC1-dependent protein synthesis underlying rapid antidepressant effect requires GABABR signaling. Neuropharmacology 2013;73:192-203
   PubMed Web of Science ®Google Scholar
• Müller HK, Wegener G, Liebenberg N, et al. Ketamine regulates the presynaptic release machinery in the hippocampus. J Psychiatr Res 2013;47(7):892-9
   PubMed Web of Science ®Google Scholar
• Bonanno G, Giambelli R, Raiteri L, et al. Chronic antidepressants reduce depolarization-evoked glutamate release and protein interactions favoring formation of SNARE complex in hippocampus. J Neurosci 2005;25(13):3270-9
   PubMed Web of Science ®Google Scholar
• Barbiero VS, Giambelli R, Musazzi L, et al. Chronic antidepressants induce redistribution and differential activation of acaM kinase II between presynaptic compartments. Neuropsychopharmacology 2007;32(12):2511-19
   PubMed Web of Science ®Google Scholar
• Hashimoto K. Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship. Cent Nerv Syst Agents Med Chem 2009;9(3):197-204
   PubMedGoogle Scholar
• Hashimoto K. Sigma-1 receptor chaperone and brain-derived neurotrophic factor: emerging links between cardiovascular disease and depression. Prog Neurobiol 2013;100(1):15-29
   PubMedGoogle Scholar
• Ishikawa M, Hashimoto K. The role of sigma-1 receptors in the pathophysiology of neuropsychiatric diseases. J Receptor Ligand Channel Res 2010;3:25-36
   Google Scholar
• Kotermanski SE, Johnson JW. Mg 2+ imparts NMDA receptor subtype selectivity to the Alzheimer’s drug memantine. J Neurosci 2009;29(9):2774-9
   PubMed Web of Science ®Google Scholar
• Murck H. Ketamine, magnesium and major depression - From pharmacology to pathophysiology and back. J Psychiatr Res 2013;47(7):955-65
   PubMed Web of Science ®Google Scholar
• Lima-Ojeda JM, Vogt MA, Pfeiffer N, et al. Pharmacological blockade of GluN2B-containing NMDA receptors induces antidepressant-like effects lacking psychotomimetic action and neurotoxicity in the perinatal and adult rodent brain. Prog Neuropsychopharmacol Biol Psychiatry 2013;45:28-33
   PubMed Web of Science ®Google Scholar
• Serafini G, Pompili M, Innamorati M, et al. Pharmacological properties of glutamatergic drugs targeting NMDA receptors and their application in major depression. Curr Pharm Des 2013;19(10):1898-922
   PubMed Web of Science ®Google Scholar
• Preskorn SH, Baker B, Kolluri S, et al. An Innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective n-methyl-d-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol 2008;28(6):631-7
   PubMed Web of Science ®Google Scholar
• Ibrahim L, Diazgranados N, Jolkovsky L, et al. A randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J Clin Psychopharmacol 2012;32(4):551-7
   PubMed Web of Science ®Google Scholar
• Chen J, Graham S, Moroni F, Simon R. A study of the dose dependency of a glycine receptor antagonist in focal ischemia. J Pharmacol Exp Ther 1993;267(2):937-41
   PubMed Web of Science ®Google Scholar
• Zhu WL, Wang SJ, Liu MM, et al. Glycine site N-methyl-D-aspartate receptor antagonist 7-CTKA produces rapid antidepressant-like effects in male rats. J Psychiatry Neurosci 2013;38(5):306-16
   PubMed Web of Science ®Google Scholar
• Li N, Liu RJ, Dwyer JM, et al. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry 2011;69(8):754-61
   PubMed Web of Science ®Google Scholar
• Bradley CA, Peineau S, Taghibiglou C, et al. A pivotal role of GSK-3 in synaptic plasticity. Front Mol Neurosci 2012;5:13
   PubMedGoogle Scholar
• Zhang XL, Sullivan JA, Moskal JR, Stanton PK. A NMDA receptor glycine site partial agonist, GLYX-13, simultaneously enhances LTP and reduces LTD at Schaffer collateral-CA1 synapses in hippocampus. Neuropharmacology 2008;55(7):1238-50
   PubMed Web of Science ®Google Scholar
• Burgdorf J, Zhang XL, Weiss C, et al. The N-methyl-d-aspartate receptor modulator GLYX-13 enhances learning and memory, in young adult and learning impaired aging rats. Neurobiol Aging 2011;32(4):698-706
   PubMed Web of Science ®Google Scholar
• Burgdorf J, Zhang XL, Nicholson KL, et al. GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. Neuropsychopharmacology 2013;38(5):729-42
   PubMed Web of Science ®Google Scholar
• Moskal JR, Kuo AG, Weiss C, et al. GLYX-13: a monoclonal antibody-derived peptide that acts as an N-methyl-D-aspartate receptor modulator. Neuropharmacology 2005;49(7):1077-87
   PubMed Web of Science ®Google Scholar
• Maeng S, Zarate CA Jr, Du J, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of a-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 2008;63(4):349-52
   PubMed Web of Science ®Google Scholar
• Moskal JR, Burch R, Burgdorf JS, et al. GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists. Expert Opin Investig Drugs 2014;23(2):243-54
   PubMed Web of Science ®Google Scholar
• Heresco-Levy U, Gelfin G, Bloch B, et al. A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression. Int J Neuropsychopharmacol 2013;16(3):501-6
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Mathews D, Ibrahim L, et al. A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression. Biol Psychiatry 2013;74(4):257-64
   PubMed Web of Science ®Google Scholar
• Mealing GAR, Lanthorn TH, Small DL, et al. Structural modifications to an N-methyl-D-aspartate receptor antagonist result in large differences in trapping block. J Pharmacol Exp Ther 2001;297(3):906-14
   PubMed Web of Science ®Google Scholar
• Zhang JC, Li SX, Hashimoto K. R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine. Pharmacol Biochem Behav 2014;116:137-41
   PubMed Web of Science ®Google Scholar
• Paul R, Schaaff N, Padberg F, et al. Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases. World J Biol Psychiatry 2009;10(3):241-4
   PubMed Web of Science ®Google Scholar
• Paslakis G, Gilles M, Meyer-Lindenberg A, Deuschle M. Oral administration of the NMDA receptor antagonist S-ketamine as add-on therapy of depression: a case series. Pharmacopsychiatry 2010;43(1):33-5
   PubMed Web of Science ®Google Scholar
• Sanderson TM, Collingridge GL, Fitzjohn SM. Differential trafficking of AMPA receptors following activation of NMDA receptors and mGluRs. Mol Brain 2011;4(1):30
   PubMedGoogle Scholar
• Unoki T, Matsuda S, Kakegawa W, et al. NMDA receptor-mediated PIP5K activation to produce PI(4,5)P2 is essential for AMPA receptor endocytosis during LTD. Neuron 2012;73(1):135-48
   PubMed Web of Science ®Google Scholar
• Svenningsson P, Bateup H, Qi H, et al. Involvement of AMPA receptor phosphorylation in antidepressant actions with special reference to tianeptine. Eur J Neurosci 2007;26(12):3509-17
   PubMed Web of Science ®Google Scholar
• Svenningsson P, Tzavara ET, Witkin JM, et al. Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). Proc Natl Acad Sci USA 2002;99(5):3182-7
   PubMed Web of Science ®Google Scholar
• Du J, Gray NA, Falke CA, et al. Modulation of synaptic plasticity by antimanic agents: the role of AMPA glutamate receptor subunit 1 synaptic expression. J Neurosci 2004;24(29):6578-89
   PubMed Web of Science ®Google Scholar
• Du J, Creson TK, Wu LJ, et al. The role of hippocampal GluR1 and GluR2 receptors in manic-like behavior. J Neurosci 2008;28(1):68-79
   PubMed Web of Science ®Google Scholar
• Dybala M, Siwek A, Poleszak E, et al. Lack of NMDA-AMPA interaction in antidepressant-like effect of CGP 37849, an antagonist of NMDA receptor, in the forced swim test. J Neural Transm 2008;115(11):1519-20
   PubMed Web of Science ®Google Scholar
• Akinfiresoye L, Tizabi Y. Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR. Psychopharmacology (Berl) 2013;230(2):291-8
   PubMed Web of Science ®Google Scholar
• Farley S, Apazoglou K, Witkin JM, et al. Antidepressant-like effects of an AMPA receptor potentiator under a chronic mild stress paradigm. Int J Neuropsychopharmacol 2010;13(9):1207-18
   PubMed Web of Science ®Google Scholar
• Wolak M, Siwek A, Szewczyk B, et al. Involvement of NMDA and AMPA receptors in the antidepressant-like activity of antidepressant drugs in the forced swim test. Pharmacol Rep 2013;65(4):991-7
   PubMed Web of Science ®Google Scholar
• Nations KR, Bursi R, Dogterom P, et al. Maximum tolerated dose evaluation of the AMPA modulator org 26576 in healthy volunteers and depressed patients: a summary and method analysis of bridging research in support of phase II dose selection. Drugs R D 2012;12(3):127-39
   PubMedGoogle Scholar
• Nations KR, Dogterom P, Bursi R, et al. Examination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: an exploratory, randomized, double-blind, placebo-controlled trial. J Psychopharmacol 2012;26(12):1525-39
   PubMed Web of Science ®Google Scholar
• Du J, Suzuki K, Wei Y, et al. The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology 2007;32(4):793-802
   PubMed Web of Science ®Google Scholar
• Dall’Igna OP, Bobermin LD, Souza DO, Quincozes-Santos A. Riluzole increases glutamate uptake by cultured C6 astroglial cells. Int J Dev Neurosci 2013;31(7):482-6
   PubMed Web of Science ®Google Scholar
• Takahashi K, Murasawa H, Yamaguchi K, et al. Riluzole rapidly attenuates hyperemotional responses in olfactory bulbectomized rats, an animal model of depression. Behav Brain Res 2011;216(1):46-52
   PubMed Web of Science ®Google Scholar
• Banasr M, Chowdhury GMI, Terwilliger R, et al. Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Mol Psychiatry 2010;15(5):501-11
   PubMed Web of Science ®Google Scholar
• Li N, He X, Zhang Y, et al. Brain-derived neurotrophic factor signalling mediates antidepressant effects of lamotrigine. Int J Neuropsychopharmacol 2011;14(8):1091-8
   PubMed Web of Science ®Google Scholar
• Abelaira HM, Réus GZ, Ribeiro KF, et al. Lamotrigine treatment reverses depressive-like behavior and alters BDNF levels in the brains of maternally deprived adult rats. Pharmacol Biochem Behav 2012;101(3):348-53
   PubMed Web of Science ®Google Scholar
• Gabriel A. Lamotrigine adjunctive treatment in resistant unipolar depression: an open, descriptive study. Depress Anxiety 2006;23(8):485-8
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Suppes T, Bowden CL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 2000;61(11):841-50
   PubMed Web of Science ®Google Scholar
• Goodwin GM, Bowden CL, Calabrese JR, et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004;65(3):432-41
   PubMed Web of Science ®Google Scholar
• Frye MA, Ketter TA, Kimbrell TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000;20(6):607-14
   PubMed Web of Science ®Google Scholar
• Normann C, Hummel B, Schärer LO, et al. Lamotrigine as adjunct to paroxetine in acute depression: a placebo-controlled, double-blind study. J Clin Psychiatry 2002;63(4):337-44
   PubMed Web of Science ®Google Scholar
• Barbosa L, Berk M, Vorster M. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry 2003;64(4):403-7
   PubMed Web of Science ®Google Scholar
• Santos MA, Rocha FL, Hara C. Efficacy and safety of antidepressant augmentation with lamotrigine in patients with treatment-resistant depression: a randomized, placebo-controlled, double-blind study. Prim Care Companion J Clin Psychiatry 2008;10(3):187-90
   PubMedGoogle Scholar
• Barbee JG, Thompson TR, Jamhour NJ, et al. A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression. J Clin Psychiatry 2011;72(10):1405-12
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Payne JL, Quiroz J, et al. An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry 2004;161(1):171-4
   PubMed Web of Science ®Google Scholar
• Brennan BP, Hudson JI, Jensen JE, et al. Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole. Neuropsychopharmacology 2010;35(3):834-46
   PubMed Web of Science ®Google Scholar
• Ibrahim L, Diazgranados N, Franco-Chaves J, et al. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs Add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology 2012;37(6):1526-33
   PubMed Web of Science ®Google Scholar